Literature DB >> 15992227

Coping in women with breast cancer in complementary and conventional care over 5 years measured by the mental adjustment to cancer scale.

Marianne Carlsson1, Maria Arman, Marie Backman, Elisabeth Hamrin.   

Abstract

OBJECTIVE: Many patients with cancer, women more often than men, use complementary and alternative medicine (CAM) and care. Our aim was to examine coping over 5 years (November 1995 to January 1999) in two samples of women with breast cancer who were treated with anthroposophic care or conventional medical treatment. The present study is part of a larger study of the outcome of anthroposophic care for women with breast cancer.
DESIGN: A nonrandomized controlled trial design was used with individual matching and repeated measurements on six occasions (at admission, 1 month, 3 months, 6 months, 1 year, and 5 years). The matching was based on the following variables: stage of disease at entry, age, treatment during the 3 months before entering the study, and prognosis.
SETTING: An anthroposophic hospital and conventional hospitals in Sweden.
SUBJECTS: Sixty (60) women treated with anthroposophic medicine and 60 women from an oncology outpatient department participated. Forty-nine (49) women in anthroposophic care and 51 in the outpatient group survived 1 year; 26 women in anthroposophic care and 31 in the outpatient group survived 5 years. INTERVENTION: An anthroposophic care program. OUTCOME MEASURE: Coping was measured using the Mental Adjustment to Cancer scale. Repeat measures of analysis of variance (ANOVA) were used for within-group comparisons, and effect size (ES) was used for between-group comparisons.
RESULTS: The women in anthroposophic care showed more passive and anxious coping on admission, but this decreased over time. In the women in anthroposophic care, there were small ES improvements in fighting spirit and passive, anxious coping at 4 of the measured timepoints compared to admission.
CONCLUSION: The choice of anthroposophic care could be seen as a possible way to cope with emotional distress in this group of women with breast cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15992227     DOI: 10.1089/acm.2005.11.441

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  6 in total

1.  Quality of Life and Patterns of Use of Complementary and Alternative Medicines Among Glioma Patients.

Authors:  Ketty Mobed; Raymond Liu; Susan Stewart; Margaret Wrensch; Lucie McCoy; Terri Rice; Michael Prados; Susan Chang
Journal:  J Support Oncol       Date:  2009 Nov-Dec

2.  Stress, coping and cognitive deficits in women after surgery for breast cancer.

Authors:  Stephanie A Reid-Arndt; Cathy R Cox
Journal:  J Clin Psychol Med Settings       Date:  2012-06

3.  Systematic review of integrative health care research: randomized control trials, clinical controlled trials, and meta-analysis.

Authors:  Raheleh Khorsan; Ian D Coulter; Cindy Crawford; An-Fu Hsiao
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-08       Impact factor: 2.629

4.  Active Participation, Mind-Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients.

Authors:  Anna-Katharin Theuser; Sophia Antoniadis; Hanna Langemann; Sonja Wasner; Katharina Grasruck; Svenja Dietzel-Drentwett; Peter A Fasching; Matthias W Beckmann; Carolin C Hack
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

5.  Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador).

Authors:  R Ziegler; Ronald Grossarth-Maticek
Journal:  Evid Based Complement Alternat Med       Date:  2008-04-11       Impact factor: 2.629

6.  Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials?

Authors:  Renatus Ziegler
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-04       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.